Cytomos has launched Celledonia™, a benchtop cell analyzer, that they say provides rapid, unbiased, and intuitive cell-specific insights. The benchtop technology was designed to reduce development and technology transfer timelines, costs, labor, and time-to-market for modalities including monoclonal antibodies (mAbs), T cell immunotherapies, and induced pluripotent stem cells (iPSCs). The company claims Celledonia leverages the power of Cytomos’ AuraCyt™ platform, which integrates a proprietary semiconductor chip with narrow-channel fluidics that focus cells (5-30 μm) close to the surface of the chip.
